ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (1169 K)

Article Toolbox
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.pep.2007.08.016    
How to Cite or Link Using DOI (Opens New Window)

Published by Elsevier Inc.

A novel immunogenic spore coat-associated protein in Bacillus anthracis: Characterization via proteomics approaches and a vector-based vaccine system

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Yu-Tsueng Liua, Shwu-Bin Linb, Cheng-Po Huanga, b and Chun-Ming Huanga, c, d, Corresponding Author Contact Information, E-mail The Corresponding Author

aMoores Cancer Center, University of California, San Diego, CA, USA

bDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taiwan

cDepartment of Medicine, Division of Dermatology, San Diego, CA, USA

dVA San Diego Healthcare Center, San Diego, CA, USA


Received 17 June 2007; 
revised 12 August 2007. 
Available online 14 September 2007.

Abstract

New generation anthrax vaccines have been actively explored with the aim of enhancing efficacies and decreasing undesirable side effects that could be caused by licensed vaccines. Targeting novel antigens and/or eliminating the requirements for multiple needle injections and adjuvants are major objectives in the development of new anthrax vaccines. Using proteomics approaches, we identified a spore coat-associated protein (SCAP) in Bacillus anthracis. An Escherichia coli vector-based vaccine system was used to determine the immunogenicity of SCAP. Mice generated detectable SCAP antibodies three weeks after intranasal immunization with an intact particle of ultraviolet (UV)-irradiated E. coli vector overproducing SCAP. The production of SCAP antibodies was detected via western blotting and SCAP-spotted antigen-arrays. The adjuvant effect of a UV-irradiated E. coli vector eliminates the necessity of boosting and the use of other immunomodulators which will foster the screening and manufacturing of new generation anthrax vaccines. More importantly, the immunogenic SCAP may potentially be a new candidate for the development of anthrax vaccines.

Keywords: Immunogenic; Spore coat; Bacillus anthracis; Proteomics; Vector; Vaccine

Article Outline

Materials and methods
Two-dimensional gel electrophoresis (2-DE)
MALDI-TOF MS
Q-TOF MS/MS sequencing and database searching
Plasmid construction and recombinant SCAP expression and purification
Proteolytic activity of SCAP
Immunization with a UV-irradiated E. coli vector-based vaccine
Antigen array printing and hybridization
Assay for apoptotic cells
Results
Identification of SCAP via proteomics
The toxic effect of SCAP
Creation of vector-based vaccine system
SCAP is an immunogenic protein
Discussion
Conclusions
Acknowledgements
References






Corresponding Author Contact InformationCorresponding author. Address: Department of Medicine, Division of Dermatology, University of California, San Diego and VA San Diego Healthcare Center, Rm 3217A, 3350 La Jolla Village Drive, San Diego, CA, USA. Fax: +1 858 642 1435.

 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.